Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- Check3 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This appears to be a minor version update and does not modify the study content or details presented on the page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page metadata. This indicates an internal update to the page’s version, with no visible changes to the study details or user-facing content.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision: v3.6.4 has been added, replacing the previous v3.6.3 revision. This indicates a small update to the page's documentation or metadata rather than substantive content changes.SummaryDifference0.0%

- Check61 days agoChange DetectedThe revision label was updated from v3.6.2 to v3.6.3, signaling a version update for the page.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, indicating a newer build of the page. This update affects only the versioning metadata displayed on the page and does not modify the study content.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page adds a recruitment status line ('No longer looking for participants') and new help sections (How to Read a Study Record, Common Questions, How to Join a Study), and it also updates the Intervention/Treatment header formatting along with the revision label to v3.6.0, reflecting a mix of usability improvements and cosmetic/version changes.SummaryDifference0.4%

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.